Genomic testing for cancer of unknown primary
Treatments studied
Part of Cancer clinical trials.
This trial is for people with cancer of unknown primary (CUP), meaning cancer that started in an unknown place in the body. It aims to use advanced genomic testing (looking at your tumor's DNA) on your stored tumor sample and blood to find clues about where the cancer began and possible treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years old or older.
- You have a confirmed diagnosis of cancer of unknown primary (CUP).
- You are able to carry out most daily activities (ECOG performance status 0 to 2).
- You have a tumor sample (from a past biopsy or surgery) that can be used for testing.
- You are willing to give blood samples on up to two separate occasions.
- You do not have a known HIV, Hepatitis B, or Hepatitis C infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radioactive medicine (Lu-177 FAP-2286) that seeks out and delivers radiation directly to cancer cells. It is for people whose cancer started in an unknown place and has not responded to their first chemotherapy.
This trial tests a combination of two drugs for a cancer that doctors cannot find where it started (cancer of unknown primary). The drugs target a protein called HER2, which is found on the surface of some cancer cells, to help stop the cancer from growing.
This trial is for people whose cancer started in an unknown place (cancer of unknown primary). It uses a special test called PaCIFiC-CUP to help classify the cancer, which may guide better treatment choices.
This study is for people with cancer that has spread to other parts of the body but where doctors cannot find the original tumor (called cancer of unknown primary). The trial aims to improve prediction of how the cancer will behave and to personalize treatment. Participants will have a biopsy of the metastatic area, and researchers will use this to better understand the cancer and guide treatment options.
This trial tests a new drug (F520) combined with two chemotherapy drugs for people whose cancer started in an unknown place in the body. It aims to see if the combination shrinks tumors and is safe.
This study aims to understand the experiences of people living with cancer of unknown primary (CUP) and their caregivers. By sharing your story, you can help improve support and care for others in the same situation.
Hear when a new Cancer of Unknown Primary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.